Lonnel Coats is Chief Executive Officer of LEXICON PHARMACEUTICALS, INC.. Currently has a direct ownership of 1.1 Million shares of LXRX, which is worth approximately $911,396. The most recent transaction as insider was on Feb 28, 2024, when has been sold 61,371 shares (Common Stock) at a price of $2.62 per share, resulting in proceeds of $160,792. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.1M
0% 3M change
20.09% 12M change
Total Value Held $911,396

LONNEL COATS Transaction History

Date Transaction Value Shares Traded Shares Held Form
Feb 28 2024
SELL
Payment of exercise price or tax liability
$160,792 $2.62 p/Share
61,371 Reduced 5.29%
1,098,068 Common Stock
Feb 28 2024
BUY
Exercise of conversion of derivative security
-
245,080 Added 17.45%
1,159,439 Common Stock
Nov 16 2023
BUY
Open market or private purchase
$94,500 $1.05 p/Share
90,000 Added 8.96%
914,359 Common Stock
Nov 10 2023
BUY
Open market or private purchase
$10,100 $1.01 p/Share
10,000 Added 1.2%
824,359 Common Stock
Jun 29 2023
BUY
Open market or private purchase
$21,600 $2.16 p/Share
10,000 Added 1.21%
814,359 Common Stock
Jun 26 2023
BUY
Open market or private purchase
$21,800 $2.18 p/Share
10,000 Added 1.23%
804,359 Common Stock
Jun 23 2023
BUY
Open market or private purchase
$25,000 $2.5 p/Share
10,000 Added 1.24%
794,359 Common Stock
Jun 22 2023
BUY
Open market or private purchase
$92,400 $2.31 p/Share
40,000 Added 4.85%
784,359 Common Stock
Feb 28 2023
SELL
Payment of exercise price or tax liability
$110,607 $2.17 p/Share
50,971 Reduced 6.41%
744,359 Common Stock
Feb 28 2023
BUY
Exercise of conversion of derivative security
-
209,327 Added 20.84%
795,330 Common Stock
Feb 28 2022
SELL
Payment of exercise price or tax liability
$136,951 $2.85 p/Share
48,053 Reduced 7.58%
586,003 Common Stock
Feb 28 2022
BUY
Exercise of conversion of derivative security
-
197,343 Added 23.74%
634,056 Common Stock
Feb 28 2021
SELL
Payment of exercise price or tax liability
$395,723 $7.19 p/Share
55,038 Reduced 11.19%
436,713 Common Stock
Feb 28 2021
BUY
Exercise of conversion of derivative security
-
192,885 Added 28.17%
491,751 Common Stock

Also insider at

BPMC
Blueprint Medicines Corp Healthcare
VERV
Verve Therapeutics, Inc. Healthcare
LC

Lonnel Coats

Chief Executive Officer
Cambridge, MA

Track Institutional and Insider Activities on LXRX

Follow LEXICON PHARMACEUTICALS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells LXRX shares.

Notify only if

Insider Trading

Get notified when an Lexicon Pharmaceuticals, Inc. insider buys or sells LXRX shares.

Notify only if

News

Receive news related to LEXICON PHARMACEUTICALS, INC.

Track Activities on LXRX